More Than a Score: What Rectal Cancer Survivors Taught Us About Recovery

Published in Cancer and Surgery

Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

What matters more after rectal cancer surgery: the score we record, or the experience our patients describe?

 

More than half of the patients in our study had severe bowel dysfunction after rectal cancer surgery. However, nearly three-quarters still described themselves as satisfied with their bowel function.

This unexpected finding challenged a question we often assume we already know the answer to: do symptom scores always reflect how patients actually feel?

 

For many people diagnosed with rectal cancer, one of the biggest worries is whether they will need a permanent stoma. Fortunately, sphincter-preserving surgery has transformed rectal cancer care. By avoiding a permanent stoma, it offers patients the possibility of maintaining normal defecation.

 

However, life after surgery can come with its own challenges.

 

Some patients experience changes in bowel habits after surgery. They may need to use the toilet more frequently (frequency), have a sudden urge to go (urgency), pass stools multiple times within a short period (clustering), pass stool in small, unsatisfying installments (fragmentation), or occasionally struggle with leakage (incontinence). These symptoms are collectively known as Low Anterior Resection Syndrome (LARS).

 

The LARS score, a validated patient-reported outcome measure, is widely used to quantify these symptoms and has consistently been associated with impaired quality of life. Higher scores indicate a greater impact on bowel function. In our study, we wanted to understand not only what the scores showed, but also how patients themselves felt about their lives after surgery.

 

What did we study?

We evaluated 42 Indian patients who had undergone sphincter-preserving surgery for rectal cancer - a population the LARS literature has largely overlooked.

 

We found that bowel symptoms after surgery were common:

  • 4% of patients had major LARS, meaning they experienced more severe bowel dysfunction.
  • 2% had minor LARS.
  • 4% had no LARS symptoms.
  • Patients with tumors located closer to the anal opening were more likely to have worse LARS scores.
  • Those undergoing lower rectal resections also tended to report more severe symptoms.

These findings were in line with what previous studies around the world have shown.

 

Nevertheless, another result surprised us.

When the numbers and the patient's experience do not match

Despite experiencing bowel symptoms:

  • 8% of patients reported that they were satisfied with their bowel function overall.
  • Even among patients with major LARS, 63.6% still reported feeling satisfied and having adapted well to life after surgery.

In other words, a high symptom score did not always mean that patients felt their quality of life was poor.

 

Why Might This Happen?

Several factors may contribute to this disconnect.

 

Survival often outweighs inconvenience.

Many patients expressed gratitude simply for being cancer-free. After confronting a life-threatening diagnosis, occasional urgency or increased frequency may be perceived as a reasonable trade-off.

 

Adaptation changes perception

Patients frequently develop coping mechanisms over time. Adjusting diet, scheduling daily activities around bowel habits, and learning about symptom triggers can improve confidence and satisfaction despite persistent symptoms.

 

Family and social support matter

In many Indian households, strong family support systems may ease the practical and emotional burden associated with bowel dysfunction.

 

Cultural context may influence symptom interpretation.

The LARS questionnaire was developed and validated predominantly in Western populations. It places significant emphasis on symptoms such as urgency and clustering.

Whether lifelong differences in diet, bowel habits, expectations of normality, and sociocultural attitudes influence how Indian patients interpret these symptoms remains uncertain. This hypothesis warrants further investigation in larger, multicentre cohorts.

 

What Does This Mean for Clinical Practice?

Our findings highlight an important message:

Scores matter, but so do conversations.

 

A high LARS score should prompt clinicians to explore how symptoms affect an individual's daily life rather than assume poor quality of life.

Conversely, patients who report satisfaction despite major LARS should not be dismissed as "doing well" without ongoing support and surveillance.

The score provides structure and comparability. The patient's voice provides meaning.

 

Looking Ahead

This was a single-center study involving a relatively small cohort, and our findings should be interpreted within these limitations. Larger prospective studies are needed to determine whether these observations are reproducible across diverse populations.

 

Nevertheless, our patients reminded us of an important truth that can easily be overlooked in survivorship care:

Recovery after cancer is not defined solely by the absence of symptoms. It is also shaped by resilience, adaptation, expectations, and the personal meaning individuals attach to their experiences.

 

As clinicians, we should continue to carefully measure bowel function.

However, we should also ask a simpler question:

"How are you living with it?"

Because the score tells us something important.

And so does the person sitting across from us.

Read the full article.

Our study, "Functional Outcomes After Sphincter-Preserving Surgery for Rectal Cancer: Exploring the Relationship Between LARS Severity and Patient Satisfaction in an Indian Cohort", is now available online through Springer Nature.

 

For researchers, clinicians, and survivorship specialists interested in patient-reported outcomes after rectal cancer surgery, we invite you to read the complete manuscript:

Article link: https://link.springer.com/article/10.1007/s12672-026-05000-5

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Rectal Cancer
Life Sciences > Biological Sciences > Cancer Biology > Cancers > Gastrointestinal Cancer > ColoRectal Cancer > Rectal Cancer
Colorectal Surgery
Life Sciences > Health Sciences > Surgery > Colorectal Surgery
  • Discover Oncology Discover Oncology

    This is a fully open access general oncology journal that aims to provide a unified forum for researchers and clinicians. The journal spans from basic and translational science, to preclinical, clinical, and epidemiology, and welcomes content that interfaces at all levels of cancer research.

Related Collections

With Collections, you can get published faster and increase your visibility.

Immune Checkpoint Inhibitors in Cancer: Mechanisms, Clinical Applications, and Future Directions

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by harnessing the body's immune system to target and eliminate tumor cells. These inhibitors, which include antibodies targeting CTLA-4, PD-1, and PD-L1, have shown remarkable efficacy in various cancer types, leading to durable responses and prolonged survival in patients who had limited treatment options. The success of ICIs in oncology has sparked a surge in research focused on understanding their mechanisms of action, identifying biomarkers for response, managing immune-related adverse events, and expanding their application to a broader range of malignancies.

However, despite the transformative impact of ICIs, many challenges remain. The majority of patients do not achieve complete responses, resistance to therapy is common, and the long-term effects of immune modulation are not fully understood. Ongoing research is crucial to optimize the use of ICIs, overcome resistance, and develop combination therapies that can enhance their efficacy.

This Collection aims to compile cutting-edge research and reviews on immune checkpoint inhibitors in cancer, encompassing a wide range of topics that reflect the current state and future directions of this rapidly evolving field. The issue will include but is not limited to the following themes:

Mechanisms of Action: Exploration of how ICIs modulate immune responses against cancer, including molecular and cellular mechanisms.

Clinical Applications: Studies on the efficacy and safety of ICIs in various cancer types, including ongoing clinical trials and real-world evidence.

Biomarkers of Response and Resistance: Research on predictive biomarkers for ICI efficacy, including genetic, proteomic, and immunological factors.

Combination Therapies: Investigations into the synergistic effects of ICIs with other treatment modalities, such as chemotherapy, radiation, targeted therapy, and other immunotherapies.

Management of Immune-Related Adverse Events (irAEs): Studies focusing on the identification, prevention, and management of irAEs associated with ICIs.

Emerging Targets and Future Directions: Reviews and original research on novel immune checkpoint targets beyond PD-1/PD-L1 and CTLA-4, and innovative therapeutic strategies in development.

Ethical, legal, and regulatory challenges arising from the ever-growing implementation of highly innovative techniques, and how to best meet such challenges in order to ensure equitable, patient-centered access to the most effective personalized/precision medicine-based diagnostics/therapeutics approaches as they become available.

We believe that this Collection will not only provide valuable insights into the current challenges and opportunities associated with ICIs but also serve as a comprehensive resource for researchers and healthcare professionals dedicated to improving cancer outcomes.

Keywords: immune checkpoint inhibitors, cancer treatment, biomarkers, immune-related adverse events, immune checkpoint targets

Publishing Model: Open Access

Deadline: Jun 30, 2026

Biomarkers and Therapeutic Targets for Central Nervous System Tumors

Central Nervous System (CNS) tumors remain a significant challenge in both research and clinical practice due to their complex biology, limited treatment options, and often poor prognosis. The identification of biomarkers is crucial for early diagnosis, prognosis, and therapeutic monitoring, while the development of novel therapeutic targets offers new opportunities to improve patient outcomes. This collection aims to bring together cutting-edge research on molecular and genetic biomarkers, tumor microenvironment interactions, immune response mechanisms, and emerging targeted therapies for CNS tumors. We welcome contributions exploring biomarker discovery, pharmacological approaches, liquid biopsy, multi-omics approaches, immune-oncology strategies, drug resistance mechanisms, and novel therapeutic interventions, including precision medicine and nanotechnology-based drug delivery systems. By fostering interdisciplinary discussions, this collection seeks to advance our understanding of CNS tumor pathophysiology and pave the way for more effective and personalised treatment strategies.

Keywords: CNS tumors, biomarkers, therapeutic targets, neuro-oncology, immunotherapy, tumor microenvironment, precision medicine, targeted therapy, drug resistance.

Publishing Model: Open Access

Deadline: Jun 30, 2026